Identification
- Summary
Cefepime is a fourth-generation cephalosporin antibiotic used in the treatment of various bacterial infections caused by susceptible bacteria, such as pneumonia, urinary tract infections, and skin infections.
- Generic Name
- Cefepime
- DrugBank Accession Number
- DB01413
- Background
Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime is active against Gram-positive and Gram-negative bacteria, with greater activity against both than third-generation antibiotics. Cefepime is usually reserved to treat severe nosocomial pneumonia, infections caused by multi-resistant microorganisms (e.g. Pseudomonas aeruginosa) and empirical treatment of febrile neutropenia.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Cefepime (DB01413)
- Weight
- Average: 480.561
Monoisotopic: 480.124959288 - Chemical Formula
- C19H24N6O5S2
- Synonyms
- (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(1-methylpyrrolidinium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
- Cefepima
- Cefepime
- Cefepimum
- External IDs
- BMY 28142
- BMY-28142
Pharmacology
- Indication
For the treatment of pneumonia (moderate to severe) caused by Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiella pneumoniae, or Enterobacter species. Also for empiric treatment of febrile neutropenic patients and uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae, when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Also for the treatment of uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible strains only) or Streptococcus pyogenes and complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter species, or Bacteroides fragilis.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime is active against Gram-positive and Gram-negative bacteria, with greater activity against both than third-generation antibiotics. Cefepime has good activity against important pathogens including Pseudomonas aeruginosa, Staphylococcus aureus, Enterobacteriaceae, and multiple drug resistant Streptococcus pneumoniae. Whereas other cephalosporins are degraded by many plasmid- and chromosome-mediated beta-lactamases, cefepime is stable and is a front line agent when infection with Enterobacteriaceae is known or suspected
- Mechanism of action
Cephalosporins are bactericidal and have the same mode of action as other beta-lactam antibiotics (such as penicillins). Cephalosporins disrupt the synthesis of the peptidoglycan layer of bacterial cell walls. The peptidoglycan layer is important for cell wall structural integrity, especially in Gram-positive organisms. The final transpeptidation step in the synthesis of the peptidoglycan is facilitated by transpeptidases known as penicillin binding proteins (PBPs).
Target Actions Organism APenicillin-binding protein 2 inhibitorEscherichia coli (strain K12) APeptidoglycan synthase FtsI inhibitorEscherichia coli (strain K12) APenicillin-binding protein 3 inhibitorPseudomonas aeruginosa APenicillin-binding protein 2 inhibitorPseudomonas aeruginosa - Absorption
The absolute bioavailability of cefepime after an IM dose of 50 mg/kg was 82.3 (±15)% in eight patients.
- Volume of distribution
- 18.0 ±2.0 L
- 0.3 ±0.1 L/kg [Pediatric]
- Protein binding
The serum protein binding of cefepime is approximately 20% and is independent of its concentration in serum.
- Metabolism
Hepatic. Cefepime is metabolized to N-methylpyrrolidine (NMP) which is rapidly converted to the N-oxide (NMP-N-oxide).
Hover over products below to view reaction partners
- Route of elimination
Elimination of cefepime is principally via renal excretion with an average (±SD) half-life of 2 (±0.3) hours and total body clearance of 120 (±8) mL/min in healthy volunteers. Cefepime is excreted in human milk.
- Half-life
2.0 (± 0.3) hours in normal patients. The average half-life in patients requiring hemodialysis was 13.5 (± 2.7) hours and in patients requiring continuous peritoneal dialysis was 19.0 (± 2.0) hours.
- Clearance
- 120 mL/min [Healthy adult male receiving a single 30-minute IV infusions of cefepime]
- 3.3 +/-1.0 mL/min/kg [Petriatic patients (2 months – 11 years of age) receiving a single IV dose]
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Symptoms of overdose include seizures, encephalopathy, and neuromuscular excitability.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Cefepime may decrease the excretion rate of Abacavir which could result in a higher serum level. Abciximab The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefepime. Aceclofenac The risk or severity of nephrotoxicity can be increased when Cefepime is combined with Aceclofenac. Acemetacin The risk or severity of nephrotoxicity can be increased when Cefepime is combined with Acemetacin. Acenocoumarol The risk or severity of bleeding can be increased when Cefepime is combined with Acenocoumarol. Acetaminophen Cefepime may decrease the excretion rate of Acetaminophen which could result in a higher serum level. Acetylsalicylic acid The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefepime. Aclidinium Cefepime may decrease the excretion rate of Aclidinium which could result in a higher serum level. Acrivastine Cefepime may decrease the excretion rate of Acrivastine which could result in a higher serum level. Acyclovir The risk or severity of nephrotoxicity can be increased when Acyclovir is combined with Cefepime. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Cefepime hydrochloride I8X1O0607P 123171-59-5 LRAJHPGSGBRUJN-OMIVUECESA-N - International/Other Brands
- Axepim / Cepimax / Cepimex
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Cefepime Injection, solution 1 g/50mL Intravenous Baxter Healthcare Corporation 2008-08-05 Not applicable US 
Cefepime for Injection Powder, for solution 1 g / vial Intramuscular; Intravenous Apotex Corporation Not applicable Not applicable Canada 
Cefepime for Injection Powder, for solution 2 g / vial Intravenous Apotex Corporation 2009-03-19 Not applicable Canada Cefepime for Injection USP Powder, for solution 1 g / vial Intramuscular; Intravenous Telip, Llc, A Subsidiary Of Teligent, Inc. Not applicable Not applicable Canada Cefepime for Injection USP Powder, for solution 2 g / vial Intravenous Telip, Llc, A Subsidiary Of Teligent, Inc. 2021-07-09 Not applicable Canada Cefepime for Injection, USP Powder, for solution 1 g / vial Intramuscular; Intravenous Qilu Pharmaceutical Co. Ltd Not applicable Not applicable Canada Cefepime for Injection, USP Powder, for solution 2 g / vial Intravenous Qilu Pharmaceutical Co. Ltd Not applicable Not applicable Canada Cefepime Hydrochloride and Dextrose Injection, solution 2 g/50mL Intravenous B. Braun Medical Inc. 2010-05-06 Not applicable US Cefepime Hydrochloride and Dextrose Injection, solution 1 g/50mL Intravenous B. Braun Medical Inc. 2010-05-06 Not applicable US Maxipime Injection, powder, for solution 2 g/1 Intravenous Cardinal Health 1996-01-18 2012-10-31 US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Apo-cefepime Powder, for solution 2 g / vial Intravenous Apotex Corporation 2018-05-14 Not applicable Canada Apo-cefepime Powder, for solution 1 g / vial Intramuscular; Intravenous Apotex Corporation 2018-05-14 Not applicable Canada Cefepime Injection, powder, for solution 2 g/20mL Intravenous WG Critical Care, LLC 2021-03-31 Not applicable US Cefepime Injection, powder, for solution 1 g/1 Intramuscular; Intravenous Apotex Corporation 2007-06-18 2019-01-31 US Cefepime Injection, powder, for solution 1 g/1 Intramuscular; Intravenous Apotex Corp. 2017-11-14 Not applicable US Cefepime Injection, powder, for solution 2 g/20mL Intravenous WG Critical Care, LLC 2014-10-10 Not applicable US Cefepime Injection, powder, for solution 2 g/1 Intravenous Apotex Corporation 2007-06-18 2019-04-30 US Cefepime Injection 2 g/1 Intravenous Sandoz 2010-12-21 2017-07-31 US Cefepime Injection, powder, for solution 1 g/1 Intramuscular; Intravenous Qilu Pharmaceutical Co., Ltd. 2016-02-01 Not applicable US Cefepime Injection, powder, for solution 1 g/1 Intramuscular; Intravenous Piramal Critical Care Inc. 2019-05-20 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image ROXIPIME 1 GR IM/IV ENJEKTABL TOZ ICEREN FLAKON, 1 ADET Cefepime (1 gr) Injection Intramuscular; Intravenous World Medicine Ilac San. Ve Tic. a.s. 2020-08-14 Not applicable Turkey 
Categories
- ATC Codes
- J01DE01 — Cefepime
- J01DE — Fourth-generation cephalosporins
- J01D — OTHER BETA-LACTAM ANTIBACTERIALS
- J01 — ANTIBACTERIALS FOR SYSTEMIC USE
- J — ANTIINFECTIVES FOR SYSTEMIC USE
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as 3'-quaternary ammonium cephalosporins. These are cephalosporins that are substituted at the 3'-position by a quaternary ammonium group.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Lactams
- Sub Class
- Beta lactams
- Direct Parent
- 3'-quaternary ammonium cephalosporins
- Alternative Parents
- N-acyl-alpha amino acids and derivatives / 2,4-disubstituted thiazoles / 1,3-thiazines / 2-amino-1,3-thiazoles / N-alkylpyrrolidines / Heteroaromatic compounds / Tetraalkylammonium salts / Tertiary carboxylic acid amides / Carboxylic acid salts / Azetidines show 14 more
- Substituents
- 1,3-thiazol-2-amine / 2,4-disubstituted 1,3-thiazole / 3'-quaternary ammonium cephalosporin / Alpha-amino acid or derivatives / Amine / Amino acid / Amino acid or derivatives / Aromatic heteropolycyclic compound / Azacycle / Azetidine show 30 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- cephalosporin, oxime O-ether (CHEBI:478164)
- Affected organisms
- Enteric bacteria and other eubacteria
Chemical Identifiers
- UNII
- 807PW4VQE3
- CAS number
- 88040-23-7
- InChI Key
- HVFLCNVBZFFHBT-ZKDACBOMSA-N
- InChI
- InChI=1S/C19H24N6O5S2/c1-25(5-3-4-6-25)7-10-8-31-17-13(16(27)24(17)14(10)18(28)29)22-15(26)12(23-30-2)11-9-32-19(20)21-11/h9,13,17H,3-8H2,1-2H3,(H3-,20,21,22,26,28,29)/b23-12-/t13-,17-/m1/s1
- IUPAC Name
- 1-{[(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-2-carboxylato-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}-1-methylpyrrolidin-1-ium
- SMILES
- CO\N=C(/C(=O)N[C@@H]1C(=O)N2[C@]1([H])SCC(C[N+]1(C)CCCC1)=C2C([O-])=O)C1=CSC(N)=N1
References
- Synthesis Reference
Vijay Handa, Anand Kamat, Meenakshisunderam Sivakumaran, "Process for preparing cefepime." U.S. Patent US20050043531, issued February 24, 2005.
US20050043531- General References
- Chapman TM, Perry CM: Cefepime: a review of its use in the management of hospitalized patients with pneumonia. Am J Respir Med. 2003;2(1):75-107. [Article]
- External Links
- Human Metabolome Database
- HMDB0015483
- KEGG Drug
- D02376
- KEGG Compound
- C08111
- PubChem Compound
- 5479537
- PubChem Substance
- 46507919
- ChemSpider
- 4586395
- BindingDB
- 50350470
- 20481
- ChEBI
- 478164
- ChEMBL
- CHEMBL186
- Therapeutic Targets Database
- DAP000455
- PharmGKB
- PA164754876
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Cefepime
- FDA label
- Download (244 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Antibiotic Reaction / Febrile Neutropenia / Leukemias / Pediatrics Cancer 1 4 Completed Treatment Bacteremia / Sepsis 1 4 Completed Treatment Diabetes Mellitus 1 4 Completed Treatment Peritoneal Dialysis Associated Peritonitis 1 4 Completed Treatment Pneumonia 1 4 Not Yet Recruiting Treatment Endocarditis 1 4 Not Yet Recruiting Treatment Pneumonia 1 4 Recruiting Prevention Aspiration / Pneumonia, Aspiration 1 4 Recruiting Treatment Febrile Neutropenia 2 4 Unknown Status Treatment Cystic Fibrosis (CF) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Antibioticos Ltd.
- Apotex Inc.
- APP Pharmaceuticals
- B. Braun Melsungen AG
- Baxter International Inc.
- Bristol-Myers Squibb Co.
- Cardinal Health
- Elan Pharmaceuticals Inc.
- GC Hanford Manufacturing Co.
- Orchid Healthcare
- Patheon Inc.
- Sagent Pharmaceuticals
- Sandoz
- Dosage Forms
Form Route Strength Injection, powder, for solution Injection Parenteral Injection, powder, for solution Parenteral 0.5 g Injection, powder, for solution Parenteral Injection, powder, for solution Parenteral 1 g Injection, powder, for solution Parenteral 2 g Injection Intramuscular; Intravenous 1 g/1 Injection Intramuscular; Intravenous 500 mg/1 Injection Intravenous 2 g/1 Injection, powder, for solution Intramuscular; Intravenous 1 g/20mL Injection, powder, for solution Intramuscular; Intravenous 2 g/1 Injection, powder, for solution Intravenous 1 g/1 Injection, powder, for solution Intravenous 100 g/1 Injection, powder, for solution Intravenous 2 g/20mL Powder Not applicable 1 g/1g Injection, powder, for solution Intramuscular; Intravenous 1 g Powder, for solution Intravenous 2 g / vial Injection, solution Intravenous 1 g/50mL Injection, solution Intravenous 2 g/50mL Injection, powder, for solution Intravenous 1000 mg Injection, powder, for solution 1 G Injection, powder, for solution 2 G Injection, powder, for solution Intramuscular; Intravenous 1 g/vial Injection, powder, for solution Intramuscular; Intravenous 2 g Injection, powder, lyophilized, for solution Intramuscular; Intravenous 1000 MG Injection, powder, for solution Intravenous 2000 mg Injection Intramuscular Injection Intramuscular; Intravenous Injection, powder, for solution Parenteral 1 G/3ML Injection, powder, for solution Parenteral 2 G/10ML Injection, powder, for solution Parenteral 500 MG/1.5ML Injection, powder, for solution Parenteral 1000 MG/3ML Injection, powder, for solution Parenteral 2000 MG/10ML Injection Injection, powder, for solution Parenteral 1000 mg Injection, powder, for solution Intramuscular; Intravenous 1 g/1 Injection, powder, for solution Intramuscular; Intravenous 500 mg/1 Injection, powder, for solution Intravenous 2 g/1 Injection, powder, for solution Intramuscular; Intravenous Powder, for solution Intramuscular; Intravenous 1 g / vial Injection, powder, for solution Intravenous Injection, powder, for solution Intravenous 2 g/vial Injection Intravenous 1 G Injection Intravenous 500 MG Powder 500 mg/1vial - Prices
Unit description Cost Unit Maxipime 2 gram vial 43.04USD vial Cefepime hcl 2 gram vial 40.36USD vial Maxipime 1 gm piggyback vial 23.24USD vial Maxipime 1 gram vial 21.7USD vial Cefepime hcl 1 gm vial 20.33USD vial Cefepime 2 gm injection 0.51USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0173 mg/mL ALOGPS logP -0.37 ALOGPS logP -4.3 ChemAxon logS -4.5 ALOGPS pKa (Strongest Acidic) 3.25 ChemAxon pKa (Strongest Basic) 4.06 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 8 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 150.04 Å2 ChemAxon Rotatable Bond Count 7 ChemAxon Refractivity 141.98 m3·mol-1 ChemAxon Polarizability 47.53 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.9819 Blood Brain Barrier - 0.9332 Caco-2 permeable - 0.6669 P-glycoprotein substrate Substrate 0.9066 P-glycoprotein inhibitor I Non-inhibitor 0.7965 P-glycoprotein inhibitor II Non-inhibitor 0.5353 Renal organic cation transporter Non-inhibitor 0.7455 CYP450 2C9 substrate Non-substrate 0.8806 CYP450 2D6 substrate Non-substrate 0.8068 CYP450 3A4 substrate Substrate 0.6023 CYP450 1A2 substrate Non-inhibitor 0.7233 CYP450 2C9 inhibitor Non-inhibitor 0.736 CYP450 2D6 inhibitor Non-inhibitor 0.8741 CYP450 2C19 inhibitor Non-inhibitor 0.6986 CYP450 3A4 inhibitor Non-inhibitor 0.8378 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8854 Ames test Non AMES toxic 0.6625 Carcinogenicity Non-carcinogens 0.9051 Biodegradation Not ready biodegradable 0.6571 Rat acute toxicity 2.3513 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9015 hERG inhibition (predictor II) Non-inhibitor 0.734
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Escherichia coli (strain K12)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Serine-type d-ala-d-ala carboxypeptidase activity
- Specific Function
- Cell wall formation; PBP-2 is responsible for the determination of the rod shape of the cell. It synthesizes cross-linked peptidoglycan from lipid intermediates.
- Gene Name
- mrdA
- Uniprot ID
- P0AD65
- Uniprot Name
- Penicillin-binding protein 2
- Molecular Weight
- 70856.1 Da
References
- Grassi GG, Grassi C: Cefepime: overview of activity in vitro and in vivo. J Antimicrob Chemother. 1993 Nov;32 Suppl B:87-94. [Article]
- Kind
- Protein
- Organism
- Escherichia coli (strain K12)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Peptidoglycan glycosyltransferase activity
- Specific Function
- Essential cell division protein that is required for the synthesis of peptidoglycan at the division septum (PubMed:1103132, PubMed:9614966). Catalyzes the synthesis of cross-linked peptidoglycan fr...
- Gene Name
- ftsI
- Uniprot ID
- P0AD68
- Uniprot Name
- Peptidoglycan synthase FtsI
- Molecular Weight
- 63876.925 Da
References
- Grassi GG, Grassi C: Cefepime: overview of activity in vitro and in vivo. J Antimicrob Chemother. 1993 Nov;32 Suppl B:87-94. [Article]
- Kind
- Protein
- Organism
- Pseudomonas aeruginosa
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Peptidoglycan glycosyltransferase activity
- Specific Function
- Not Available
- Gene Name
- pbpB
- Uniprot ID
- Q51504
- Uniprot Name
- Cell division protein
- Molecular Weight
- 62855.78 Da
References
- Grassi GG, Grassi C: Cefepime: overview of activity in vitro and in vivo. J Antimicrob Chemother. 1993 Nov;32 Suppl B:87-94. [Article]
- Kind
- Protein
- Organism
- Pseudomonas aeruginosa
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Penicillin binding
- Specific Function
- Not Available
- Gene Name
- pbpA
- Uniprot ID
- Q9X6V3
- Uniprot Name
- Penicillin-binding protein 2
- Molecular Weight
- 72212.855 Da
References
- Grassi GG, Grassi C: Cefepime: overview of activity in vitro and in vivo. J Antimicrob Chemother. 1993 Nov;32 Suppl B:87-94. [Article]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Symporter activity
- Specific Function
- Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cat...
- Gene Name
- SLC22A5
- Uniprot ID
- O76082
- Uniprot Name
- Solute carrier family 22 member 5
- Molecular Weight
- 62751.08 Da
References
- Ganapathy ME, Huang W, Rajan DP, Carter AL, Sugawara M, Iseki K, Leibach FH, Ganapathy V: beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J Biol Chem. 2000 Jan 21;275(3):1699-707. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Proton-dependent oligopeptide secondary active transmembrane transporter activity
- Specific Function
- Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
- Gene Name
- SLC15A1
- Uniprot ID
- P46059
- Uniprot Name
- Solute carrier family 15 member 1
- Molecular Weight
- 78805.265 Da
References
- Ganapathy ME, Huang W, Rajan DP, Carter AL, Sugawara M, Iseki K, Leibach FH, Ganapathy V: beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J Biol Chem. 2000 Jan 21;275(3):1699-707. [Article]
- Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Peptide:proton symporter activity
- Specific Function
- Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
- Gene Name
- SLC15A2
- Uniprot ID
- Q16348
- Uniprot Name
- Solute carrier family 15 member 2
- Molecular Weight
- 81782.77 Da
References
- Ganapathy ME, Huang W, Rajan DP, Carter AL, Sugawara M, Iseki K, Leibach FH, Ganapathy V: beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J Biol Chem. 2000 Jan 21;275(3):1699-707. [Article]
- Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [Article]
Drug created at July 19, 2007 15:47 / Updated at January 16, 2022 18:54